Leerink Partnrs Issues Pessimistic Outlook for ITCI Earnings

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Intra-Cellular Therapies in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings of $0.50 per share for the year, down from their previous forecast of $0.55. The consensus estimate for Intra-Cellular Therapies' current full-year earnings is ($0.59) per share.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $161.40 million for the quarter, compared to analysts' expectations of $157.74 million. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. Intra-Cellular Therapies's quarterly revenue was up 45.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.45) EPS.

A number of other research firms have also issued reports on ITCI. Canaccord Genuity Group lifted their target price on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a "buy" rating in a report on Thursday, June 20th. Mizuho raised their target price on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, June 21st. Needham & Company LLC restated a "buy" rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $130.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Finally, UBS Group lowered their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has an average rating of "Moderate Buy" and a consensus price target of $96.62.

Intra-Cellular Therapies Stock Up 3.4 %

NASDAQ ITCI traded up $2.59 on Thursday, reaching $78.68. 455,506 shares of the stock traded hands, compared to its average volume of 878,900. Intra-Cellular Therapies has a 12 month low of $45.50 and a 12 month high of $84.89. The company has a market cap of $8.31 billion, a price-to-earnings ratio of -65.59 and a beta of 1.00. The firm's fifty day simple moving average is $74.25 and its 200 day simple moving average is $72.34.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several large investors have recently made changes to their positions in the business. Kapitalo Investimentos Ltda bought a new position in shares of Intra-Cellular Therapies during the 4th quarter worth about $26,000. Headlands Technologies LLC acquired a new position in Intra-Cellular Therapies in the 1st quarter valued at approximately $32,000. Fidelis Capital Partners LLC bought a new stake in shares of Intra-Cellular Therapies in the 1st quarter worth approximately $53,000. Summit Securities Group LLC acquired a new stake in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $56,000. Finally, CWM LLC increased its position in shares of Intra-Cellular Therapies by 83.9% during the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 626 shares during the period. Institutional investors and hedge funds own 92.33% of the company's stock.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 53,013 shares of the company's stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Sharon Mates sold 53,013 shares of the company's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company's stock, valued at approximately $80,970,388.85. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mark Neumann sold 18,714 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 175,316 shares of company stock valued at $13,037,345 over the last three months. 3.40% of the stock is currently owned by insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.